These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34107886)

  • 1. The Patient, Investigator, Nurse, Carer Questionnaire (PINC-Q): a cross-sectional, retrospective, non-interventional study exploring the impact of less frequent medication administration with paliperidone palmitate 3-monthly as maintenance treatment for schizophrenia.
    Pungor K; Sanchez P; Pappa S; Attal J; Leopold K; Steegen G; Vita A; Marsella C; Verrijcken C; Lahaye M; Wooller A
    BMC Psychiatry; 2021 Jun; 21(1):300. PubMed ID: 34107886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact on carer burden when stable patients with schizophrenia transitioned from 1-monthly to 3-monthly paliperidone palmitate.
    Lencer R; Garcia-Portilla MP; Bergmans P; Gopal S; Mathews M; Wooller A; Pungor K
    Compr Psychiatry; 2021 May; 107():152233. PubMed ID: 33711781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health Outcomes Among Patients Diagnosed with Schizophrenia in the US Veterans Health Administration Population Who Transitioned from Once-Monthly to Once-Every-3-Month Paliperidone Palmitate: An Observational Retrospective Analysis.
    Patel C; El Khoury A; Huang A; Wang L; Baser O; Joshi K
    Adv Ther; 2019 Oct; 36(10):2941-2953. PubMed ID: 31396809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medication adherence, healthcare resource utilization, and costs among Medicaid beneficiaries with schizophrenia treated with once-monthly paliperidone palmitate or once-every-three-months paliperidone palmitate.
    Lin D; Pilon D; Zhdanava M; Joshi K; Lafeuille MH; Côté-Sergent A; Vermette-Laforme M; Lefebvre P
    Curr Med Res Opin; 2021 Apr; 37(4):675-683. PubMed ID: 33507838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
    Mathews M; Pei H; Savitz A; Nuamah I; Hough D; Alphs L; Gopal S
    Clin Drug Investig; 2018 Aug; 38(8):695-702. PubMed ID: 29882073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical guidance for dosing and switching from paliperidone palmitate 1 monthly to 3 monthly formulation in schizophrenia.
    Gopal S; Vermeulen A; Nandy P; Ravenstijn P; Nuamah I; Buron Vidal JA; Berwaerts J; Savitz A; Hough D; Samtani MN
    Curr Med Res Opin; 2015 Nov; 31(11):2043-54. PubMed ID: 26306819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting.
    Joshi K; Lafeuille MH; Brown B; Wynant W; Emond B; Lefebvre P; Tandon N
    Curr Med Res Opin; 2017 Oct; 33(10):1763-1772. PubMed ID: 28741387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of 3-Monthly Long-Acting Injectable Paliperidone Palmitate in Schizophrenia: A Retrospective, Real-World Analysis of Population-Based Health Records in Spain.
    Gutiérrez-Rojas L; Sánchez-Alonso S; García Dorado M; López Rengel PM
    CNS Drugs; 2022 May; 36(5):517-527. PubMed ID: 35460508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discontinuation and relapse with paliperidone palmitate three-monthly for maintenance of schizophrenia: Two year follow-up of use in clinical practice.
    Wallman P; Clark I; Taylor D
    J Psychopharmacol; 2021 Sep; 35(9):1091-1098. PubMed ID: 33908302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of 3-monthly paliperidone palmitate on hospitalisation in a naturalistic schizophrenia cohort - A five-year mirror image study.
    Wallman P; Clark I; Taylor D
    J Psychiatr Res; 2022 Apr; 148():131-136. PubMed ID: 35123325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from clozapine to paliperidone palmitate-3-monthly improved obesity, hyperglycemia and dyslipidemia lowering antipsychotic dose equivalents in a treatment-resistant schizophrenia cohort.
    Martínez-Andrés JA; García-Carmona JA
    Int Clin Psychopharmacol; 2020 May; 35(3):163-169. PubMed ID: 31851035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projecting the Potential Effect of Using Paliperidone Palmitate Once-Monthly and Once-Every-3-Months Long-Acting Injections Among Medicaid Beneficiaries with Schizophrenia.
    Basu A; Benson C; Alphs L
    J Manag Care Spec Pharm; 2018 Aug; 24(8):759-768. PubMed ID: 30058979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.
    Schreiner A; Caspi A; Bergmans P; Cherubin P; Keim S; Lara E; Pinchuk I; Schuepbach D; Suleman S; Hargarter L
    Psychopharmacology (Berl); 2017 Jan; 234(1):3-13. PubMed ID: 27815602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Projecting the economic outcomes of switching patients with schizophrenia from oral atypical antipsychotics to once-monthly, once-every-3-months, and once-every-6-months paliperidone palmitate.
    Morrison L; Lin D; Benson C; Ghelerter I; Vermette-Laforme M; Lefebvre P; Pilon D
    J Manag Care Spec Pharm; 2023 Feb; 29(2):161-171. PubMed ID: 36354209
    [No Abstract]   [Full Text] [Related]  

  • 15. Adherence, Persistence, Readmissions, and Costs in Medicaid Members with Schizophrenia or Schizoaffective Disorder Initiating Paliperidone Palmitate Versus Switching Oral Antipsychotics: A Real-World Retrospective Investigation.
    Dickson MC; Nguyen MM; Patel C; Grabich SC; Benson C; Cothran T; Skrepnek GH
    Adv Ther; 2023 Jan; 40(1):349-366. PubMed ID: 36348142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans.
    Emond B; El Khoury AC; Patel C; Pilon D; Morrison L; Zhdanava M; Lefebvre P; Tandon N; Joshi K
    Curr Med Res Opin; 2019 Mar; 35(3):407-416. PubMed ID: 30556739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans.
    DerSarkissian M; Lefebvre P; Joshi K; Brown B; Lafeuille MH; Bhak RH; Hellstern M; Bobbili P; Shiner B; El Khoury AC; Young-Xu Y
    Clin Ther; 2018 Sep; 40(9):1496-1508. PubMed ID: 30145029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.
    Savitz AJ; Xu H; Gopal S; Nuamah I; Ravenstijn P; Janik A; Schotte A; Hough D; Fleischhacker WW
    Int J Neuropsychopharmacol; 2016 Jul; 19(7):. PubMed ID: 26902950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical and economic impact of three-monthly long-acting formulation of paliperidone palmitate versus the one-monthly formulation in the treatment of schizophrenia in France: A cost-utility study.
    Arteaga Duarte CH; Fakra E; Van Gils C; Guillon P
    Encephale; 2019 Dec; 45(6):459-467. PubMed ID: 31542210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiation of quarterly palmitate paliperidone in French clinical practice: Results from the observational, cross-sectional OPTIMUS study.
    Gary C; Déal C; Boursicot-Beuzelin J; Falissard B; Giordana JY; Fakra E; Samalin L; Bouju S
    Pharmacoepidemiol Drug Saf; 2022 Mar; 31(3):334-342. PubMed ID: 34897888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.